Literature DB >> 33182044

Diosmetin alleviates acute kidney injury by promoting the TUG1/Nrf2/HO-1 pathway in sepsis rats.

Weiyang Wang1, Shimin Zhang2, Fan Yang1, Jie Xie1, Jiajun Chen1, Zhanfei Li3.   

Abstract

BACKGROUND: We aimed to study the effects and the underlying mechanisms of Diosmetin (DIOS) in rats with sepsis-induced acute kidney injury (AKI).
METHODS: The AKI model in RMCs was induced using LPS, and the cells were then treated with DIOS. Cell viability, apoptosis, inflammatory response, and antioxidant were measured using MTT, Flow cytometry, ELISA, and Lucigenin assay, respectively. The correlation between TUG1 and Nrf2 was confirmed by RNA pull-down and RNA immunoprecipitation. Real-time quantitative PCR and Western blot were performed to detect the expressions of gene and proteins during the development of AKI. The effects of lncRNA-TUG1 silencing and Nrf2 silencing on cell physiological functions were detected. Moreover, a rat sepsis-induced AKI model followed by Hematoxylin & Eosin (H&E) and immunofluorescence staining were performed.
RESULTS: The experimental concentration of DIOS was determined to be 20 μM. After LPS treatment, the activity of RMCs was decreased, the apoptosis rate, inflammation and oxidative stress damage were increased, moreover, the expression of Nrf2/HO-1 signal axis was inhibited and caspase-3 was activated. However, DIOS significantly reversed these effects caused by LPS treatment, and increased the expression of lncRNA-TUG1, but lncRNA-TUG1 silencing effectively reversed the effects of DIOS. In addition, lncRNA-TUG1 was found to interact with Nrf2. Overexpression of TUG1 could reduce the damage of LPS caused to cell physiological functions, which were reversed by siNrf2. Thus, DIOS treatment could improve the physiological and pathological damages of renal tissues in AKI rats.
CONCLUSION: DIOS may reduce sepsis-induced AKI through enhancing the TUG1/Nrf2/HO-1 pathway.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute kidney injury; Diosmetin; Nrf2; Sepsis; lncRNA-TUG1

Mesh:

Substances:

Year:  2020        PMID: 33182044     DOI: 10.1016/j.intimp.2020.106965

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  5 in total

1.  LncRNA TUG1 attenuates ischaemia-reperfusion-induced apoptosis of renal tubular epithelial cells by sponging miR-144-3p via targeting Nrf2.

Authors:  Sheng Zhao; Wu Chen; Wei Li; Weimin Yu; Siqi Li; Ting Rao; Yuan Ruan; Xiangjun Zhou; Cong Liu; Yucheng Qi; Fan Cheng
Journal:  J Cell Mol Med       Date:  2021-09-21       Impact factor: 5.310

2.  Diosmetin Protects against Cardiac Hypertrophy via p62/Keap1/Nrf2 Signaling Pathway.

Authors:  Yingying Guo; Dan Li; Xian-Feng Cen; Hong-Liang Qiu; Yu-Lan Ma; Yi Liu; Si-Hui Huang; Li-Bo Liu; Man Xu; Qi-Zhu Tang
Journal:  Oxid Med Cell Longev       Date:  2022-02-22       Impact factor: 6.543

3.  Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics.

Authors:  Jin Wang; Shanbo Ma; Long Li; Yuhan Chen; Qian Yang; Feiyan Wang; Meiling Zheng; Shan Miao; Xiaopeng Shi
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

Review 4.  Non-Coding RNAs in Kidney Diseases: The Long and Short of Them.

Authors:  Juan Antonio Moreno; Eya Hamza; Melania Guerrero-Hue; Sandra Rayego-Mateos; Cristina García-Caballero; Mercedes Vallejo-Mudarra; Laurent Metzinger; Valérie Metzinger-Le Meuth
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

5.  Inhibition of Podocytes DPP4 Activity Is a Potential Mechanism of Lobeliae Chinensis Herba in Treating Diabetic Kidney Disease.

Authors:  Xinyu Wang; Jiaqing Xiang; Guixiao Huang; Lin Kang; Guangyan Yang; Han Wu; Kewei Jiang; Zhen Liang; Shu Yang
Journal:  Front Pharmacol       Date:  2021-12-07       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.